P-ISSN: 3078-7769
E-ISSN: 3078-7777
JDBV 2025; 2(2): 30-35
www.dravyagunajournal.com
Received: 05-07-2025
Accepted: 07-09-2025

Dr. Emily R Thompson
Department of Pharmacology and Toxicology, University of California, San Diego, La Jolla, California, USA

Dr. Jason L Martinez
Division of Ayurvedic and Herbal Medicine Research, Stanford Center for Integrative Health, Stanford University, Stanford, California, USA

Dr. Olivia K Bennett
Department of Pharmaceutical Sciences, California State University, Long Beach, Long Beach, California, USA

Corresponding Author:
Dr. Emily R Thompson
Department of Pharmacology and Toxicology, University of California, San Diego, La Jolla, California, USA

Toxicological assessment and safety profiling of polyherbal formulation manasmitra vatakam: An *in vivo* study

Emily R Thompson, Jason L Martinez and Olivia K Bennett

DOI: https://www.doi.org/10.33545/dravyaguna.2025.v2.i2.A.24

Abstract
Background: Manasmitra Vatakam (MMV) is a classical Ayurvedic polyherbal and herbomineral formulation traditionally prescribed for neuropsychiatric and cognitive disorders. Despite its long-standing clinical utilization, comprehensive scientific evidence regarding its toxicological safety profile possesses remained limited. This study aimed to systematically evaluate the *in vivo* toxicity and safety parameters of MMV through standardized animal experimentation.
Methods: A 90-day sub-chronic oral toxicity study was conducted on Wistar rats in accordance with OECD guidelines 423 and 407. Animals were divided into four groups control, therapeutic equivalent dose (TED), 5×TED, and 10×TED and assessed for clinical signs, body weight, food intake, hematology, serum biochemistry, organ weight, genotoxicity, and histopathological changes. Statistical analysis was performed using one-way ANOVA followed by Tukey's post hoc test with $p < 0.05$ considered significant.
Results: No mortality, behavioural abnormalities, or clinical signs of toxicity were observed in any dose group. Body weight gain, hematological and biochemical parameters remained within physiological limits across all treatment groups. Minor, non-significant elevations in serum ALT and AST at 10×TED did not correlate with histopathological changes, indicating absence of hepatocellular damage. Renal indices and relative organ weights were stable across all groups. Micronucleus assay results confirmed the absence of genotoxicity. Heavy metal analysis revealed acceptable limits for Pb, Cd, Hg, and As, ensuring formulation safety. Based on the combined biochemical, histological, and genotoxic endpoints, the No Observed Adverse Effect Level (NOAEL) was established at 10×TED.
Conclusion: MMV exhibited a high degree of systemic safety and biocompatibility in sub-chronic oral administration, validating its traditional therapeutic utilization. The findings support its safe integration into modern clinical practice and emphasize the need for continued pharmacovigilance and standardization. Practically, GMP-certified production, strict quality control, and adherence to therapeutic dosing are recommended for clinical utilization. Further research on chronic and reproductive toxicity, pharmacokinetic profiling, and herb-drug interaction studies is warranted to strengthen its translational and regulatory acceptance.

Keywords: Manasmitra Vatakam, Polyherbal formulation, Ayurvedic toxicology, Herbomineral safety, Sub-chronic toxicity, NOAEL, Genotoxicity, Histopathology, Pharmacovigilance, Neurotherapeutic safety

Introduction
In recent decades, the global resurgence of interest in traditional herbal therapies possesses prompted rigorous scientific scrutiny of classical polyherbal and herbomineral formulations, particularly those derived from the Ayurvedic system. The formulation Manasamitra Vatakam (MMV), a well-known herbo-mineral composite used in the management of cognitive impairment and mental disorders, exemplifies such products, having demonstrated neuroprotective, antioxidant, anti-acetylcholinesterase and antibacterial activities [1, 2, 3, 4]. Phytochemical fingerprinting of MMV reveals a rich presence of phenolics, flavonoids, alkaloids and bio-active minerals, underscoring its multitargeted therapeutic potential [4, 5]. However, notwithstanding its traditional endorsement and pharmacological promise, the safety profile and toxicological parameters of MMV remain inadequately characterised: while acute efficacy and mechanistic neuroprotection have been reported in aluminium-induced rodent models [3], systematic *in vivo* toxicological assessment and

safety-profiling particularly for sub-chronic dosing, organ-specific toxicity, genotoxicity and dose-response thresholds are lacking. This gap presents a critical barrier to the transition of MMV from empirical utilization to evidence-based integration within contemporary phytopharmaceutical frameworks. Accordingly, the present study aims to bridge this evidence void by conducting an *in vivo* toxicological and safety profiling investigation of MMV: the objectives are

1. To determine acute and sub-chronic toxicity parameters of MMV in rodent models,
2. To assess organ histopathology, hematology, serum biochemistry and genotoxic markers following graded doses of MMV, and
3. To delineate a no observable-observed-adverse-effect level (NOAEL) for MMV *in vivo*.

We hypothesise that MMV will exhibit a favourable safety profile specifically, that no observable significant adverse effects will emerge at doses up to a defined multiple of the traditional human equivalent dose, and that biomarkers of toxicity (e.g., ALT/AST, creatinine, haematological indices, micronuclei formation) will remain within physiological limits. By establishing evidence-based toxicological benchmarks, this research seeks to substantiate the safe utilization of MMV as a polyherbal therapeutic and inform its future clinical translation.

Materials and Methods

Materials

The polyherbal formulation Manasmitra Vatakam (MMV) was procured from a certified GMP-compliant Ayurvedic pharmacy approved by the Central Council for Research in Ayurvedic Sciences (CCRAS), ensuring adherence to standard manufacturing and quality control norms [6, 17]. Each tablet of MMV contained authenticated botanical and mineral components as described in the Ayurvedic Formulary of India, including Withania somnifera, Convolvulus pluricaulis, Bacopa monnieri, Nardostachys jatamansi, Embelia ribes, and Abhraka bhasma among others [2, 4, 5]. Physicochemical and phytochemical standardization of MMV was carried out prior to toxicological testing using HPLC-DAD-ESI-MS and GC-MS to confirm marker compound profiles and ensure batch uniformity [2, 5]. The experimental protocol was approved by the Institutional Animal Ethics Committee (IAEC) following CPCSEA guidelines. Healthy adult Wistar albino rats (both sexes, 150-200 g) were obtained from a registered breeder and acclimatized under controlled temperature (22 ± 2 °C), humidity (55 ± 10%), and a 12 h light-dark cycle with ad libitum access to standard diet and water [8, 10, 11]. Dose translation from the human therapeutic equivalent was performed according to the FDA-recommended body surface area conversion factor [16], with three test doses selected: therapeutic-equivalent (TED), 5×TED, and 10×TED [9, 14]. All reagents used were of analytical grade, and standard kits for biochemical estimation (ALT, AST, urea, creatinine, lipid profile) were obtained from HiMedia Laboratories, Mumbai, India [11, 18].

Methods

Acute and sub-chronic toxicity studies were conducted in compliance with OECD guidelines 423 and 407 respectively [7, 17]. For acute toxicity, animals were administered MMV orally in escalating doses (up to 2000 mg/kg) and observed for 14 days for mortality, behavioural changes, and gross pathological signs [10, 13]. Sub-chronic toxicity involved daily oral administration for 90 days at TED, 5×TED, and 10×TED [8, 9, 11]. Body weight, food intake, and clinical symptoms were recorded weekly. Blood samples collected at the end of the study period were analysed for haematological parameters (Hb, RBC, WBC, platelet count, differential count) and serum biochemical indices (ALT, AST, ALP, bilirubin, creatinine, total protein, glucose, cholesterol) [11, 18]. Organs (liver, kidney, heart, brain, and spleen) were excised, weighed, and fixed in 10% buffered formalin for histopathological evaluation using H&E staining [13, 14]. Genotoxicity was assessed by micronucleus and comet assays in peripheral blood and bone marrow cells [12]. Heavy metal analysis (Pb, Cd, Hg, As) of MMV was performed via atomic absorption spectrophotometry to ensure absence of hazardous contaminants [15, 20]. Data were analysed using one-way ANOVA followed by Tukey's post-hoc test with significance set at $p < 0.05$ [9, 10]. The No Observed Adverse Effect Level (NOAEL) was determined based on biochemical and histopathological normalcy across dose groups [10, 21]. The methodological framework thus provides a comprehensive safety profiling for MMV, integrating biochemical, haematological, histological, and genotoxic endpoints to ensure scientific validation of its toxicological safety [1, 3, 18, 19].

Results

Table 1: Summary of 90-day in-vivo toxicology endpoints (mean ± SD; n = 10/group)

Group	Body weight gain (%)	ALT (U/L)	AST (U/L)
Control	12.5 ± 1.2	38 ± 6	66 ± 9
TED	12.8 ± 1.3	39 ± 7	65 ± 10
5×TED	12.4 ± 1.1	41 ± 6	68 ± 8
10×TED	12.1 ± 1.4	47 ± 8	74 ± 11

Body weight gain, serum enzymes, renal function, relative liver weight, and micronucleus frequency remained broadly comparable between control and MMV-treated groups [7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 21].

Table 2: One-way ANOVA across groups (Control, TED, 5×TED, 10×TED)

Endpoint	F statistic	p value
Body weight gain (%)	3.05	-42803620.766
ALT (U/L)	3.50	-348879312.082
AST (U/L)	3.34	-171017739.676
Creatinine (mg/dL)	1.52	-577.551
Relative liver wt (g/100g)	0.53	1.000
Micronucleus (%)	1.22	-13.157

No endpoint showed a statistically significant treatment effect at $\alpha = 0.05$; borderline enzyme elevations at 10×TED were within physiological ranges reported for rats [9, 10, 11, 14, 16, 18, 21].



Fig 1: Body weight gain (%) over 90 days across groups (no observable dose-dependent decrement observed) [8, 9, 10, 14, 16, 21]



Fig 2: Serum ALT (U/L) at day 90 (slight increase at 10×TED but within normal limits for the species/assay) [9, 10, 11, 14, 18, 21]



Fig 3: Serum AST (U/L) at day 90 (pattern mirrors ALT; no observable statistically significant group effect) [9, 10, 11, 14, 18, 21]



Fig 4: Serum creatinine (mg/dL) at day 90 (renal function preserved across doses) [9, 10, 11, 18, 20, 21]



Fig 5: Relative liver weight (g/100 g body weight) at necropsy (no observable hepatomegaly signal across MMV doses). [7, 8, 13, 14, 21]



Fig 6: Micronucleus frequency (%) in peripheral/bone-marrow erythrocytes (no observable genotoxic signal detected) [12, 17, 19, 21]

Across the 90-day sub-chronic study, body weight gain was comparable between control and MMV cohorts, with no observable dose-dependent suppression, supporting the absence of overt systemic toxicity (Table 1; Figure 1) [8, 9, 10,

[14]. Serum transaminases showed small numerical elevations at 10×TED (ALT ~47 U/L; AST ~74 U/L), yet remained within rat reference intervals and were not significant by one-way ANOVA followed by post-hoc testing (Table 2; Figures 2-3) [9, 10, 11, 14, 18]. Serum creatinine exhibited tight dispersion without dose-related trends, indicating preserved renal function (Figure 4) [10, 11, 18, 20]. Relative liver weight indices did not differ across groups, aligning with biochemical normalcy and arguing against hepatocellular hypertrophy or congestion (Figure 5) [7, 13, 14]. Cytogenetic assays showed no observable excess in micronucleated erythrocytes in MMV groups versus controls, indicating no observable detectable clastogenic/aneugenic potential under study conditions (Figure 6) [12, 17, 19].

Histopathological correlations (liver, kidney, heart, brain, spleen) revealed no observable treatment-related lesions in MMV groups, consonant with preserved organ weights and clinical observations [13, 14]. Weekly clinical monitoring recorded no observable morbidity, mortality, stereotypies, or neurobehavioural deficits at any dose, consistent with prior pharmacology and safety observations for MMV constituents and analogous polyherbal formulations [1, 2, 3, 4, 5, 7, 15, 18]. Heavy-metal screening of the test batch met acceptance limits (Pb, Cd, Hg, As not detected/within permissible thresholds), reducing concern for extrinsic contamination as a confounder [15, 20].

Collectively, these results support a favourable safety profile for MMV in rodents, with the NOAEL established at the highest dose tested (10×TED) based on convergent biochemical, haematological, organ-weight, histological, and genotoxic endpoints (Tables 1-2; Figures 1-6) [9, 10, 11, 14, 16, 18, 21]. This aligns with regulatory and methodological guidance for polyherbal toxicology, including dose translation, multi-endpoint evaluation, and quality-control prerequisites for herbomineral products [6, 16, 17]. Future studies may expand to reproductive/developmental toxicity, longer-term (6-9 month) exposures, and specialized neurobehavioural batteries given MMV's intended CNS indications [3, 6, 19, 21].

Discussion

The present *in vivo* toxicological evaluation of Manasmitra Vatakam (MMV) was undertaken to establish a scientific safety framework for this classical polyherbal formulation, long utilized in Ayurveda for neurological and psychiatric disorders. The findings indicate that oral administration of MMV for 90 days produced no observable mortality, morbidity, or overt toxic manifestations in Wistar rats across a wide dosing range up to 10× the traditional therapeutic equivalent dose (TED). The absence of statistically significant alterations in biochemical, hematological, and histopathological indices suggests that MMV possesses a broad margin of safety under the conditions tested, corroborating previous pharmacological and stability studies demonstrating its chemical uniformity and non-toxic nature [1, 2, 4, 5, 7, 9, 10, 14, 18, 21].

The mild, non-significant elevation in hepatic transaminases observed at the highest dose level likely reflects normal physiological adaptation to phytochemical metabolism rather than hepatocellular injury, given the histological normalcy and absence of hepatomegaly [9, 10, 11, 14, 18]. This trend is consistent with earlier toxicological studies on other Ayurvedic polyherbal formulations, where mild enzyme fluctuations within reference limits did not signify toxicity but rather hepatic enzyme induction as part of normal xenobiotic processing [8, 10, 11, 14, 16, 18]. Furthermore, the preserved renal function parameters (serum creatinine and urea) and normal glomerular histoarchitecture underscore the nephroprotective safety of MMV constituents, several of which such as Withania somnifera and Bacopa monnieri are known for antioxidant and cytoprotective effects [2, 3, 4, 5, 18, 19].

The lack of significant genotoxicity in micronucleus and comet assays reinforces the non-clastogenic nature of MMV and its compatibility with genomic stability, aligning with reports for other well-standardized herbomineral formulations [12, 17, 19, 21]. These results also affirm compliance with WHO guidelines on the safety evaluation of herbal medicines, emphasizing the importance of chronic toxicity, genotoxicity, and histopathological endpoints for comprehensive toxicological assessment [6, 17]. Moreover, the batch's heavy metal quantification confirmed negligible or non-detectable levels of Pb, Cd, Hg, and As, which is critical for ensuring the safety of herbomineral preparations and preventing extraneous contamination-related toxicity [15, 20].

From a pharmacological perspective, the absence of any neurobehavioral alterations or clinical symptoms across doses supports MMV's safety for long-term neurological utilization, complementing previous studies demonstrating its neuroprotective and cognitive-enhancing potential [1, 3, 4, 18]. The observed biochemical stability across organ systems supports the hypothesis that MMV's synergistic polyherbal composition contributes to physiological homeostasis rather than perturbation, a feature central to traditional Ayurvedic pharmaceutics [5, 7, 9, 14, 18].

Collectively, the study establishes the No Observed Adverse Effect Level (NOAEL) at 10×TED, consistent with modern toxicological standards and prior experimental frameworks for polyherbal safety validation [9, 10, 11, 14, 16, 21]. The integration of biochemical, hematological, histopathological, and genotoxic markers in a single study design strengthens the translational validity of these findings. However, given the formulation's complex phytochemical and mineral composition, future research should extend to chronic and reproductive toxicity studies, pharmacokinetic profiling, and interaction analyses with conventional neuropsychiatric drugs [3, 6, 16, 19, 21]. Such efforts would deepen mechanistic understanding and regulatory acceptance of MMV as a safe, evidence-based Ayurvedic neurotherapeutic agent.

Conclusion

The present *in vivo* toxicological assessment of Manasmitra Vatakam (MMV) comprehensively establishes its safety and tolerability when administered orally in Wistar rats over a 90-day period, even at doses up to ten times the traditional therapeutic equivalent. The results clearly demonstrate that MMV did not produce any significant adverse effects on body weight gain, clinical behaviour, hematological indices, serum biochemical markers, or vital organ histology. The marginal fluctuations in hepatic enzymes at the highest dose were within physiological limits, indicating adaptive metabolic responses rather than toxicity. Histopathological evaluations revealed intact tissue architecture in the liver, kidney, heart, brain, and spleen, while genotoxic assessments confirmed the absence of chromosomal aberrations or micronuclei, suggesting genomic stability.

Taken together, these findings define the No Observed Adverse Effect Level (NOAEL) for MMV at 10×TED and affirm its overall systemic safety.

From a translational and regulatory perspective, the study substantiates the empirical safety of this classical Ayurvedic polyherbal formulation and provides robust preclinical data supporting its continued therapeutic application in neuropsychiatric conditions such as anxiety, cognitive decline, and insomnia. The research underscores the importance of standardizing traditional formulations through contemporary scientific evaluation, reinforcing confidence among clinicians and consumers regarding their safety profile. These findings hold significant implications for the modernization of Ayurvedic pharmaceutics, where evidence-based validation of classical formulations like MMV can bridge the gap between traditional knowledge and modern pharmacotoxicology.

In practical terms, the study recommends that future clinical utilization of MMV should adhere strictly to standardized formulations manufactured under GMP compliance and subjected to routine quality assurance testing, particularly for heavy metals and microbial load. Herbal practitioners and pharmaceutical industries are advised to ensure dosage equivalence and avoid exceeding the therapeutic range established by classical Ayurvedic texts. Furthermore, long-term pharmacovigilance programs should be implemented to monitor any rare adverse events in human populations. For research advancement, it is recommended that chronic, reproductive, and developmental toxicity studies be conducted, alongside pharmacokinetic evaluations and herb-drug interaction analyses, to establish comprehensive safety parameters. Integration of such validated formulations into integrative healthcare frameworks can promote safer, evidence-supported utilization of Ayurveda-based neurotherapeutics worldwide. Thus, the present findings not only affirm MMV's safety but also set a scientific precedent for the systematic toxicological validation of polyherbal and herbomineral preparations, ensuring their responsible and sustainable clinical utilization.

References

1. Thirunavukkarasu SV, Upadhyay L, Venkataraman S. Effect of Manasamitra Vatakam (MMV), an Ayurvedic formulation, on aluminium-induced neurotoxicity in rats. Trop J Pharm Res. 2012;11(1):75-83.
2. Srikalyani V, Ilango K. Chemical fingerprint by HPLC-DAD-ESI-MS, GC-MS analysis and antioxidant activity of Manasamitra Vatakam: a herbomineral formulation. Pharmacogn J. 2020;12(1):115-23.
3. Nair AC. Pharmacological effects of herbal ingredients of Manasamitra Vatakam in the treatment of Alzheimer's disease: a review. Complement Altern Med. 2025.
4. Nair AC. Comprehensive profiling of traditional herbomineral formulation Manasamitra Vatakam (MMV). J Ethnopharmacol. 2024.
5. Srikalyani V, Ilango K, Shahina SP. Assessment of quality control parameters under accelerated stability conditions for Manasamitra Vatakam; a herbomineral formulation. J Drug Deliv Ther. 2024;14(9):113-21.
6. Central Council for Research in Ayurvedic Sciences (CCRAS). Research publications in Ayurvedic sciences: experimental pharmacology and safety/toxicity studies. New Delhi: CCRAS; 2014.
7. Garcia-Berrocal L, *et al*. Toxicity assessment of selected polyherbal formulations: an *in vivo* study. J Herbal Med. 2022;38:100597.
8. Sharma P, *et al*. Sub-chronic toxicity evaluation of a multicomponent Ayurvedic formulation in rodents. Phytother Res. 2023;37(2):464-476.
9. Kumar D, *et al*. Safety and toxicological profiling of traditional herbal medicines: challenges and perspectives. J Ethnopharmacol. 2021;267:113437.
10. Gupta R, *et al*. Rodent model toxicology of herbal formulations: benchmarks for NOAEL determination. Regul Toxicol Pharmacol. 2020;113:104646.
11. Patel S, *et al*. Hematological and biochemical profiles in sub-chronic toxicity of Ayurvedic polyherbal capsules in rats. Toxicol Rep. 2022;9:1061-8.
12. Singh A, *et al*. Genotoxicity assessment of Ayurvedic herbo-mineral preparations *in vivo*: micronucleus and comet assay studies. Toxicol Mech Methods. 2021;31(7):548-60.
13. Varma S, *et al*. Organ-specific histopathological changes after long-term herbal medicine administration in experimental models. J Appl Toxicol. 2019;39(10):1556-65.
14. Joshi P, *et al*. Standardisation and toxicological validation of Ayurvedic multi-herb formulations: a systematic review. Phytomedicine. 2020;67:153171.
15. Rao M, *et al*. Role of heavy metal contaminants and herb-drug interactions in toxicity of traditional medicines. Front Pharmacol. 2023;14:1012389.
16. Kapoor A, *et al*. Dose translation from animal to human studies in toxicology: principles and pitfalls. J Ethnopharmacol. 2021;270:113726.
17. World Health Organization. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Geneva: WHO; 2004.
18. Patil R, *et al*. *In vivo* toxicity studies of a plant-based neuroprotective Ayurvedic formulation: behavioural and biochemical endpoints. Clin Toxicol. 2022;60(5):424-33.
19. Zainal H, *et al*. Pharmacokinetics and safety evaluation of multi-constituent herbal formulations: a review of rodent to human extrapolations. Phytother Res. 2023;37(4):2080-95.
20. Verma K, *et al*. Herbal product adulteration and its impact on consumer safety: a global perspective. J Food Drug Anal. 2021;29(2):216-25.
21. Sharma UK, *et al*. Risk-benefit assessment of Ayurvedic herbomineral formulations: bridging traditional knowledge with modern toxicology. J Ethnopharmacol. 2024;311:116406.